Intracellular metabolic pathways control immune tolerance

Trends in Immunology

Volumn 33, Issue 1, 2012, Pages 1-7

  Procaccini, Claudio ^a   Galgani, Mario ^a   De Rosa, Veronica ^a   Matarese, Giuseppe ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN;

CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIFESTYLE; NONHUMAN; NUTRITIONAL STATUS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; INTRACELLULAR SPACE; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84855303303     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.09.002     Document Type: Review

References (103)

1. Sakaguchi S., et al. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
2. Zhou X., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10:1000-1007.
3. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
4. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
5. Finlay D., Cantrell D.A. Metabolism, migration and memory in cytotoxic T cells. Nat. Rev. Immunol. 2011, 11:109-117.
6. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
7. Winer S., et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 2009, 15:921-929.
8. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33:301-311.
9. Peter C., et al. mTOR signalling and metabolic regulation of T cell differentiation. Curr. Opin. Immunol. 2010, 5:655-661.
10. Lord G.M., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394:897-901.
11. Matarese G., et al. Regulatory CD4 T cells: sensing the environment. Trends Immunol. 2008, 29:12-17.
12. Matarese G., La Cava A. The intricate interface between immune system and metabolism. Trends Immunol. 2004, 25:193-200.
13. De Rosa V., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26:241-255.
14. Frauwirth K.A., et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002, 16:769-777.
15. Wieman H.L., et al. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 2007, 18:1437-1446.
16. Gingras A.C., et al. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001, 15:807-826.
17. Fox C.J., et al. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 2005, 5:844-852.
18. Bental M., Deutsch C. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn. Reson. Med. 1993, 29:317-326.
19. Borsellino G., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
20. Lee K., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
21. Delgoffe G.M., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30:832-844.
22. Procaccini C., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010, 33:929-941.
23. Michalek R.D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 2011, 186:3299-3303.
24. Shi L.Z., et al. HIF1{alpha}-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208:1367-1376.
25. Dang E.V., et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011, 146:772-784.
26. Chen C., et al. The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells. Cell Cycle 2009, 15:1158-1160.
27. Kraaij M.D., et al. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:17686-17691.
28. Kim D.H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
29. Sarbassov D.D., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
30. Laplante M., Sabatini D.M. mTOR signalling at a glance. J. Cell Sci. 2009, 122:3589-3594.
31. Holz M.K., Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 2005, 280:26089-26093.
32. Düvel K., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
33. Delgoffe G.M., et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-303.
34. Sauer S., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7797-7802.
35. Haxhinasto S., et al. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 2008, 205:565-574.
36. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188:287-296.
37. Ng W.F., et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001, 98:2736-2744.
38. Battaglia M., et al. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
39. Battaglia M., et al. Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 2006, 55:1571-1580.
40. Strauss L., et al. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 2007, 178:320-329.
41. Zeiser R., et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-462.
42. Burchill M.A., et al. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 2007, 178:280-290.
43. Yao Z., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007, 109:4368-4375.
44. Basu S., et al. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J. Immunol. 2008, 180:5794-5798.
45. Valmori D., et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J. Immunol. 2006, 177:944-949.
46. Zheng Y., et al. Anergic T cells are metabolically anergic. J. Immunol. 2009, 183:6095-6101.
47. Mandapathi M., et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 2010, 285:7176-7186.
48. Vukmanovic-Stejic M., et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 2006, 116:2829-2830.
49. Sato K., et al. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy 2009, 11:936-946.
50. Symonds M.E., et al. Nutritional programming of the metabolic syndrome. Nat. Rev. Endocrinol. 2009, 5:604-610.
51. Maury E., et al. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell Endocrinol. 2010, 15:1-16.
52. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 14:860-867.
53. Rasouli N., et al. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 2008, 93:64-73.
54. MacLaren R., et al. Adipokines and the immune system: an adipocentric view. Adv. Exp. Med. Biol. 2008, 632:1-21.
55. Dixit V.D. Adipose-immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J. Leukoc. Biol. 2008, 84:882-892.
56. Brose N., Rosenmund C. Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters. J. Cell Sci. 2002, 115:4399-4411.
57. Lee J.Y., et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 2003, 278:37041-37051.
58. Weigert C., et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor kappa B. J. Biol. Chem. 2004, 279:23942-23952.
59. Gao Z., et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol. 2004, 18:2024-2034.
60. Ozcan U., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
61. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89:2548-2556.
62. Halberg N., et al. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. North. Am. 2008, 37:753-768.
63. Bilan P.J., et al. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch. Physiol. Biochem. 2009, 115:176-190.
64. Bourlier V., et al. Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab. 2009, 35:251-260.
65. Lumeng C.N., et al. T-ing up inflammation in fat. Nat. Med. 2009, 15:846-847.
66. Duan W., et al. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003, 144:2446-2453.
67. Maswood N., et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:18171-18176.
68. Kubo C., et al. The effects of dietary restriction on immune function and development of autoimmune disease in BXSB mice. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:3145-3149.
69. Muthukumar A. Age associated alterations in costimulatory and adhesion molecule expression in lupus-prone mice are attenuated by food restriction with n-6 and n-3 fatty acids. J. Clin. Immunol. 2004, 24:471-480.
70. Galgani M., et al. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J. Immunol. 2010, 185:7474-7479.
71. Piccio L., et al. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J. Leukoc. Biol. 2008, 8:940-948.
72. Harrison D.E., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
73. Härle P., Straub R.H. Leptin is a link between adipose tissue and inflammation. Ann. N. Y. Acad. Sci. 2006, 1069:454-462.
74. Donia M., et al. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmun. 2009, 33:135-140.
75. Esposito M., et al. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 2010, 220:52-63.
76. Jiang G.X., et al. Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes. Arch. Med. Res. 2009, 40:424-426.
77. Becker T., et al. FOXO-dependent regulation of innate immune homeostasis. Nature 2010, 463:369-373.
78. Hardie D.G. The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci. 2004, 117:5479-5487.
79. Woods A., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 2003, 13:2004-2008.
80. Hawley S.A., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
81. Nath N., et al. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 2009, 182:8005-8014.
82. Yang Y., et al. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J. 2005, 24:1021-1032.
83. Solomon J.M., et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell Biol. 2006, 26:28-38.
84. Yeung F., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
85. Rodgers J.T., et al. Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature 2005, 3:113-118.
86. Bordone L., et al. SIRT1 regulates insulin secretion by repressing UCP-2 in pancreatic beta cells. PLoS Biol. 2006, 4:e31.
87. Picard F., et al. SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature 2004, 17:771-776.
88. Gao X., et al. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol. 2001, 62:1299-1308.
89. Zhang J., et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 2009, 119:3048-3058.
90. van Loosdregt J., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
91. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
92. Lin L., et al. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity 2004, 21:203-213.
93. Kerdiles Y.M., et al. Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat. Immunol. 2009, 10:176-184.
94. Ouyang W., et al. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity 2009, 30:358-371.
95. Kerdiles Y.M., et al. Foxo transcription factors control regulatory T cell development and function. Immunity 2010, 33:890-904.
96. Ouyang W., et al. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 2010, 11:618-627.
97. Harada Y., et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J. Exp. Med. 2010, 207:1381-1391.
98. Cao Z., et al. TRAF6 is a signal transducer for interleukin-1. Nature 1996, 383:443-446.
99. Wu H., Arron J.R. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003, 25:1096-1105.
100. Ye H., et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002, 418:443-447.
101. Deng L., et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103:351-361.
102. King C.G., et al. Cutting edge: requirement for TRAF6 in the induction of T cell anergy. J. Immunol. 2008, 180:34-38.
103. Pearce E.L., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.